{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:49:09Z","timestamp":1769597349472,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00508-013-0469-1","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T13:10:56Z","timestamp":1385989856000},"page":"79-89","source":"Crossref","is-referenced-by-count":18,"title":["\u00d6sterreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013","Austrian 3e-recommendations for diagnosis and management of gout 2013"],"prefix":"10.1007","volume":"126","author":[{"given":"Judith","family":"Sautner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Zwerina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard F.","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"469_CR1","doi-asserted-by":"crossref","unstructured":"Li C, Hsieh MC, Chang SJ. Metabo lic syndrome, diabetes, and hyperuricemia. Curr Opin. Rheumatol. 2013 Mar;25(2):210\u20136.","DOI":"10.1097\/BOR.0b013e32835d951e"},{"issue":"17","key":"469_CR2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"469_CR3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjcard.2011.09.042","volume":"109","author":"MG Kaya","year":"2012","unstructured":"Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109(4):486\u201391.","journal-title":"Am J Cardiol"},{"key":"469_CR4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301\u201311.","journal-title":"Ann Rheum Dis"},{"key":"469_CR5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"469_CR6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 ACR guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012 Oct;64(19):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"19","key":"469_CR7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 ACR guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2021 Oct;64(19):1447\u201361.","journal-title":"Arthritis Care Res"},{"key":"469_CR8","doi-asserted-by":"crossref","unstructured":"Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 10.1136\/annrheumdis-2013\u2013203325.","DOI":"10.1136\/annrheumdis-2013-203325"},{"key":"469_CR9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2009.123687","volume":"69","author":"HJ Janssens","year":"2010","unstructured":"Janssens HJ, Janssen M, van den Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69:1255\u20136.","journal-title":"Ann Rheum Dis"},{"key":"469_CR10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/RHU.0b013e3181945b79","volume":"15","author":"A Malik","year":"2009","unstructured":"Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22\u20134.","journal-title":"J Clin Rheumatol"},{"key":"469_CR11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1148\/radiol.11102485","volume":"261","author":"KN Glazebrook","year":"2011","unstructured":"Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516\u201324.","journal-title":"Radiology"},{"key":"469_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jmu.2011.01.003","volume":"19","author":"KL Lai","year":"2011","unstructured":"Lai KL, Chiu YM. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7\u201313.","journal-title":"J Med Ultrasound"},{"issue":"10","key":"469_CR13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.amjmed.2010.03.027","volume":"123","author":"V Bhole","year":"2010","unstructured":"Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010 Oct;123(10):957\u201361.","journal-title":"Am J Med"},{"issue":"2","key":"469_CR14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.atherosclerosis.2005.09.020","volume":"187","author":"A Hozawa","year":"2006","unstructured":"Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006 Aug;187(2):401\u20137.","journal-title":"Atherosclerosis"},{"issue":"6","key":"469_CR15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","volume":"37","author":"MJ Bos","year":"2006","unstructured":"Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun;37(6):1503\u20137.","journal-title":"Stroke"},{"issue":"1","key":"469_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 Jan;49(1):141\u20136.","journal-title":"Rheumatology"},{"issue":"1","key":"469_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/rheumatology\/kes223","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013 Jan;52(1):127\u201334.","journal-title":"Rheumatology"},{"issue":"11","key":"469_CR18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/annonc\/mdm338","volume":"18","author":"AM Strasak","year":"2007","unstructured":"Strasak AM, Rapp K, Hilbe W, et al. VHM & PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol. 2007 Nov;18(11):1893\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"469_CR19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb;169(4):342\u201350.","journal-title":"Arch Intern Med"},{"key":"469_CR20","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","volume":"371","author":"HJ Janssens","year":"2008","unstructured":"Janssens HJ, Jannse M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854\u201360.","journal-title":"Lancet"},{"key":"469_CR21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: 24h outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"469_CR22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","volume":"46","author":"RE Willburger","year":"2007","unstructured":"Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology. 2007;46(7):1126\u201332.","journal-title":"Rheumatology"},{"key":"469_CR23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093\u2013103","journal-title":"N Engl J Med"},{"key":"469_CR24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","volume":"336","author":"HK Choi","year":"2008","unstructured":"Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309\u201312.","journal-title":"BMJ"},{"key":"469_CR25","doi-asserted-by":"crossref","unstructured":"Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 69(9):1677\u201382.","DOI":"10.1136\/ard.2009.124230"},{"key":"469_CR26","doi-asserted-by":"crossref","unstructured":"Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficay and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):63.","DOI":"10.1186\/ar2978"},{"issue":"9","key":"469_CR27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh JA;Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"469_CR28","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429\u201332.","journal-title":"J Rheumatol"},{"issue":"5","key":"469_CR29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","volume":"17","author":"HE Paulus","year":"1974","unstructured":"Paulus HE, Schlosstein LH Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo controlled study od probenecid-treated pateints. Arthritis Rheum. 1974;17(5):609\u201314.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"469_CR30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, Mysler E, Lin HY, et al. Cnakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"469_CR31","first-page":"104","volume":"11","author":"H Karimzadeh","year":"2006","unstructured":"Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11(2):104\u20137.","journal-title":"J Res Med Sci"},{"issue":"2","key":"469_CR32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412\u201321.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"469_CR33","first-page":"21","volume":"3","author":"T Ohue","year":"1991","unstructured":"Ohue T, Yamamoto T, et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Japanese J Rheumatology. 1991;3(1):21\u20137.","journal-title":"Japanese J Rheumatology"},{"key":"469_CR34","unstructured":"De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind- randomized study. Eur Rev Med Pharmacol Sci. 2007;11:179\u201384."},{"key":"469_CR35","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"26","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology. 2007;26:1372\u201374.","journal-title":"Rheumatology"},{"issue":"5","key":"469_CR36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","volume":"55","author":"F Perez-Ruiz","year":"2006","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786\u201390.","journal-title":"Arthritis Rheum"},{"key":"469_CR37","doi-asserted-by":"crossref","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u201325.","DOI":"10.1002\/art.20405"},{"issue":"7","key":"469_CR38","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.110272","volume":"38","author":"N Dalbeth","year":"2011","unstructured":"Dalbeth N, McQueen FM, Singh JA, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities. J Rheumatol. 2011;38(7):1458\u201361.","journal-title":"J Rheumatol"},{"issue":"9","key":"469_CR39","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888\u201393.","journal-title":"J Rheumatol"},{"issue":"4","key":"469_CR40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","volume":"50","author":"PP Khanna","year":"2011","unstructured":"Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740\u201345.","journal-title":"Rheumatology"},{"issue":"4","key":"469_CR41","first-page":"620","volume":"26","author":"WJ Taylor","year":"2008","unstructured":"Taylor WJ, Colvine K, Gregory K, et al. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620\u201326.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"469_CR42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase fort he treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711\u201320.","journal-title":"JAMA"},{"issue":"6","key":"469_CR43","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"4","key":"469_CR44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophy in chronic gout. Arthritis Rheum. 2002;47(4):356\u201360.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"469_CR45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"EW Campion","year":"1987","unstructured":"Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421\u20136.","journal-title":"Am J Med"},{"issue":"8","key":"469_CR46","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","volume":"6","author":"M Kanbay","year":"2011","unstructured":"Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"469_CR47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","volume":"39","author":"M Kanbay","year":"2007","unstructured":"Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227\u201333.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"469_CR48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan:47(1):51\u20139.","journal-title":"Am J Kidney Dis"},{"key":"469_CR49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0b013e3182314d40","volume":"17","author":"F Perez-Ruiz","year":"2011","unstructured":"Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349\u201355.","journal-title":"J Clin Rheumatol"},{"key":"469_CR50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0030-1248293","volume":"35","author":"PM Haindl","year":"2010","unstructured":"Haindl PM, Rintelen B, Brezinschek HP, et al. \u00d6sterreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie \u2013 Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt Rheumatol. 2010;35:251\u20139.","journal-title":"Akt Rheumatol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-013-0469-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0469-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:58:48Z","timestamp":1559095128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-013-0469-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":50,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s00508-013-0469-1","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}